Abstract WP5: Outcomes of Pre-Stroke Use of Metformin in Acute Ischemic Stroke Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis

Hatem Tolba,Sherief Ghozy,Madona Pakkam,Alejandro A Rabinstein,David F Kallmes
DOI: https://doi.org/10.1161/str.55.suppl_1.wp5
IF: 10.17
2024-02-03
Stroke
Abstract:Stroke, Volume 55, Issue Suppl_1, Page AWP5-AWP5, February 1, 2024. Background:Diabetes mellitus (DM) is one of the risk factors for acute ischemic stroke, usually leading to poor prognosis. While DM can reduce the effect of intravenous thrombolysis, metformin can have a positive outcome on AIS patients. The outcomes of stroke in diabetic patients receiving metformin is largely unexplored. In the present study we performed a systematic review to assess the effect of metformin on AIS outcomes in diabetic patients.Methods:A systematic review of literature was performed following PRISMA guideline. PubMed, Embase, Scopus and Web of science were used for the literature search. Study outcomes such as modified Rankin Scale (mRS 0-2) at discharge, symptomatic intracranial hemorrhage (sICH) and 90-day mortality were extracted from the full text and analysis were performed to calculate 95% confidence intervals with pooled odds ratio for all the outcomes.Results:Total of six studies were included in the analysis with a total of 5390 patients taking metformin and 6039 patients without metformin. Favorable mRS of 0-2 was significantly higher among patients taking metformin (OR 1.52, 95% CI 1.21:1.93). The mortality rate was significantly lower in metformin group (OR 0.51, 95% CI 0.42:0.61). These results favor the beneficial effect of taking metformin among DM patients with AIS.Conclusion:Overall, chronic use of metformin seems to be beneficial in AIS patients with DM. There is a trend of favorable outcomes of mRS and Mortality, with a non-statistical significance increase of sICH.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?